Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tibulizumab Dose A · 1 trial · 1 indication
AN count is calculated based on the sum of the abscesses and inflammatory nodules across different anatomical areas
| Arm | Type | Description |
|---|---|---|
| Tibulizumab Dose A | EXPERIMENTAL | Subcutaneous injection |
| Tibulizumab Dose B | EXPERIMENTAL | Subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Tibulizumab Dose A | BIOLOGICAL | Anti BAFF/IL-17 antibody. ZB-106 |
| Tibulizumab Dose B | BIOLOGICAL | Anti BAFF/IL-17 antibody. ZB-106 |
| Placebo | OTHER | ZB-106 Placebo |
Inclusion Criteria: * Male or female, 18 to 70 years of age * ≥6-month history of Hidradenitis suppurativa (HS) * Total AN (abscess and inflammatory nodule) count ≥5 * HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III Exclusion Criteria: * Draining tunnel...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | secukinumab |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Eltrekibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Tibulizumab Dose A is an investigational monoclonal antibody being studied for the treatment of Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Tibulizumab Dose A targets and inhibits IL17A and TNFSF13B, two proteins involved in inflammatory pathways. By blocking these targets, the drug aims to reduce the inflammation associated with Hidradenitis Suppurativa.
Tibulizumab Dose A is being developed by Zura Bio Limited, a biopharmaceutical company traded on the stock exchange under the ticker ZURA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Hidradenitis Suppurativa.
Tibulizumab Dose A is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies, and its safety and effectiveness are still being evaluated in clinical trials.
Tibulizumab Dose A is being evaluated in a Phase 2 clinical trial with the identifier NCT06993610. This randomized, double-blind, placebo-controlled study is enrolling 225 participants with Hidradenitis Suppurativa across the United States, Canada, Germany, Hungary, Poland, and Spain.
Tibulizumab Dose A is a specific dose of the drug tibulizumab, which is a monoclonal antibody targeting IL17A and TNFSF13B. The 'Dose A' designation refers to a particular dosing regimen being tested in clinical trials for Hidradenitis Suppurativa.